CD274 and triple-negative breast carcinoma: Furthermore, antibodies targeting PD-L1 glycosylation, such as gPD-L1, can block the PD-1/PD-L1 interaction, enhance PD-L1 internalization and degradation, and exhibit potent antitumor activity in triple-negative breast cancer models when used in antibody–drug conjugates (ADCs) [13, 65].